You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Microglia and Brain Macrophages for Glioma Progression: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor: Yuqi Zheng , Manuel B. Graeber

Evidence is accumulating that the tumour microenvironment (TME) has a key role in the progression of gliomas. Non-neoplastic cells in addition to the tumour cells are therefore finding increasing attention. Microglia and other glioma-associated macrophages are at the centre of this interest especially in the context of therapeutic considerations. New ideas have emerged regarding the role of microglia and, more blood-derived brain macrophages in glioblastoma (GBM) progression. 

  • epigenetics
  • exosomes
  • “Janus” genes
  • “Janus” pathways

1. Introduction

Microglia and recently blood/bone marrow-derived macrophages (BMDM) constitute the largest population of glioma infiltrating cells (e.g., [1]) and it is now accepted that their increased presence correlates with glioma progression and reduced patient survival [2]. Interestingly, there are significant differences between the two cell populations and also in between microglia cells within the tumour microenvironment (TME) [3][4][5][6].

2. Heterogeneity of Cells in TME

It has been demonstrated that microglia and BMDM display distinct phenotypic signatures and localisations within GBM indicating complexity and diversity of the myeloid compartment in malignant glioma [7][8].

2.1. Macrophage Scavenger Receptor 1 (MSR1/CD204)

It is becoming increasingly clear that endothelial cells are a key component in organising the perivascular niche and sustaining the survival and stemness of glioma stem cells GSCs [9]. Recent accumulating evidence indicated that GSCs predominantly reside in a perivascular niche [10][11] and usually surround by tumour-associated macrophages and microglia [12]. A previous study by Yi et al. has further reported that GSCs are better at recruiting microglia than glioma cells as GSCs expressed more Chemokine (C-C motif) ligand 2 (CCL2), Chemokine (C-C motif) ligand 5 (CCL5), Chemokine (C-C motif) ligand 7 (CCL7), Vascular endothelial growth factor A (VEGF-A) and neurotensin (NTS) than glioma cells that infiltrate the brain tissue [12]. In addition, tumour associated macrophages and microglia (TAMs) maintain the phenotype of glioma-stem cells by releasing TGF-β1, which in turn promotes glioma growth and invasion [13]. MSR1 (CD204) is a class A macrophage scavenger receptor and pattern recognition molecule associated with a pro-tumourigenic phenotype of brain macrophages [14]. High levels of MSR1+ (CD204) are associated with increased expression of immune checkpoint markers PD-L1 and TIM3 which raise the possibility that MSR1+ may contribute to T cell exhaustion [15][16]. A recent study employing single-cell RNA sequencing (scRNA-seq) reported that while BMDM aggregate perivascularly and within necrotic foci, microglia expression signatures are enriched within the glioma infiltration front (“tumour edge”). Furthermore, the increased presence of blood-derived tumour-associated macrophages correlated with shorter survival times [7]. Sørensen and Zhang et al. have shown that the number of MSR1+ glioma-associated microglia/macrophages increases with malignancy grade [14][17]. A later study performed mRNA transcriptome profiling followed by pathway and connectivity network analysis (STRING, https://www.string-db.org/; accessed on 1 November 2022) revealed that the accumulation of MSR1+ microglia/macrophages in glioblastoma correlates with an interleukin-6-enriched profile and poor survival [18]. Sørensen and Kristensen [18] further demonstrated that MSR1+ microglia/BMDM accumulate perivascularly and around necrotic areas and that they often co-reside with stem-like GBM cells expressing the marker, podoplanin (PDPN) [18]. Thus, MSR1+ microglia/BDMDs may support stem-like GBM cells and the progression of GBM in perivascular and necrotic niches.

2.2. Purinergic Receptor P2Y12 (P2RY12)

Results from recent flow cytometry experiments indicate that P2RY12 and CD49 may be used to distinguish microglia from BMDM in GBM [7][8]. In line with this, a single-cell image analysis study by Woolf et al. [19] reported that P2RY12 and TMEM119 label microglia in GBM and the authors further proposed that the markers can be used to discriminate microglia from BMDM. Of note, patients with high P2RY12 expression survived longer. Moreover, a higher microglia to BMDM ratio in GBM conferred a survival advantage that was independent of O-6-methylguanine-DNA methyltransferase (MGMT) methylation status [19]. Interestingly, activation of P2Y12 receptors causes extension of microglial cell processes [20][21]. It is noteworthy that phagocytic GBM-associated microglia and macrophages have also been observed in the non-necrotic parts of (pseudo)palisading GBM necrosis [20][21]. Importantly, microglia/macrophages in the GBM resection zone have been suggested to function as part of a glioma stem cell niche at the tumour border [22][23] which is important for tumour recurrence. It is suggested that they express a distinct gene signature [24]. The supportive influence of microglial cells on glioma growth is now established beyond doubt and can even be reproduced in a xenograft model [24]. Interestingly, microglia seem to exert a sex-specific influence in the TME [25] which may help to explain why GBM is more common and aggressive in male patients. In fact, the hijacking of sexual immune privilege by GBM has been identified as an immune evasion strategy of the glioma [25][26][27].

3. Mechanisms Underlying the Recruitment of Microglia and BMDM into Glioma Tissue

3.1. Secreted Phosphoprotein 1 (Spp1)

Secreted phosphoprotein 1 (Spp1), also known as osteopontin (OPN), is a glycophosphoprotein expressed by various cell types, including macrophages, T-cells, osteoblasts, epithelial cells and tumour cells. Moreover, expression of Spp1 can regulate cell-matrix interactions by binding to CD44 and integrin receptors thus mediating cell adhesion, chemotaxis, angiogenesis and resistance to apoptosis [28]. Notably, Spp1 expression which like CD68 [29] is especially high in mesenchymal GBM, correlates with both tumour grade and the extent of macrophage infiltration. GBM and glioblastoma stem cells (GSCs) use Spp1 to recruit macrophages into the TME [30]. Integrin αvβ5 (ITGαvβ5), a key receptor for Spp1, is highly expressed on GBM-infiltrating macrophages [30]. This is in line with previous findings by Ellert-Miklaszewska et al. that Spp1 and lactadherin enable glioma cells to gain an advantage through M2 reprogramming of tumour-infiltrating brain macrophages [31]. Therefore, Spp1 is likely to play a key role in the progression of GBM.

3.2. Periostin (POSTN)

POSTN is a disulfide-linked cell adhesion protein which belongs to the fasciclin (Fas) family [32]. Recent studies have revealed that POSTN contributes to malignant tumour progression by supporting metastatic colonisation of breast cancer stem cells through upregulation of Wnt signalling [33]. A study by Zhou et al. [34] has suggested that BMDM are the main source of macrophages in GBM and that their recruitment from the bloodstream is stimulated by GBM-secreted periostin (POSTN) that interacts with integrin αvβ3 (ITGαvβ3) on BMDMs. As expected, POSTN knockout mice show significantly extended survival times. It is noteworthy that POSTN is preferentially expressed by putative GSCs expressing SOX2 and OLIG2, respectively [34]. This is in keeping with the results of Guo et al. [35] who reported that hypoxia promotes glioma-associated macrophage infiltration via POSTN.

3.3. Nuclear and Secreted IL-33

IL-33, a member of the IL-1 cytokine family, is secreted as an alarmin by damaged or necrotic cells [36]. It is now clear that IL-33 plays a pro-tumorigenic role in various cancers including glioma [36]. De Boeck and colleagues [37] recently suggested that both the nuclear and secreted form of IL-33 are present within tumour cells in ~50% of human glioma specimens and GBM murine models. In addition, IL-33 was previously shown to associate with chromatin and be involved in the regulation of gene transcription [38]. Using multiplex cytokine/chemokine analysis, these authors further demonstrated that nuclear IL-33 facilitates tumour growth by triggering glioma-mediated expression of inflammatory cytokines (LIF, IL-6, IL-8, IL-1RN, IL-1β and secreted IL-33 [37]. Strikingly, a subset of microglia in the IL-33+ xenografts also expressed a significant amount of IL-33 and showed enrichment in pro-inflammatory cytokines, Spp1 (osteopontin), and the lipid metabolism gene, Apoe. These microglial cells further displayed a notable upregulation of the monocyte chemoattractant genes (CCL2, CCL3, and CCL12). Activation of monocyte chemoattractant genes fuels further recruitment of immune cells to the glioma microenvironment [37]. Conversely, loss of nuclear IL-33 resulted in significantly smaller IL-33-associated tumour burden and increased overall survival. Furthermore, elevated levels of both nuclear and soluble IL-33 were associated with enhanced activation of AIF1 (Iba1)+ resident microglia and recruitment of CD163+ BMDM [37]. In addition, neutralising IL-33 effects by-means of anti-IL-33 and anti-CCL2 (which is up-regulated by recombinant IL-33) antibodies significantly reduced the recruitment of microglia and BMDM [37].

3.4. Programmed Cell Death Protein 10 (PDCD10)/CXC Motif Chemokine Ligand 2 (CXCL2)/CXCR2 Signalling

PDCD10 is an evolutionarily conserved protein expressed by neurons, astrocytes, endothelial and cancer cells. Zhang et al. [39] recently reported that overexpression of PDCD10 by GBM cells promotes tumour progression via recruitment of microglia and BMDM. Furthermore, PDCD10 up-regulation is followed by an increase in CXC motif chemokine ligand 2 (CXCL2) and resulting activation of CXCR2 in microglia. In sum, CXCL2-CXCR2 signalling stimulated by PDCD10 appears to be a key mechanism in the crosstalk between GBM cells and microglia/macrophages that promotes tumour progression.

3.5. Slit Guidance Ligand 2 (SLIT2)-Roundabout 1 and 2 (ROBO1/2)

SLITs are evolutionarily conserved polypeptides that bind to cells expressing ROBO receptors. SLIT-ROBO binding activates the recruitment of adaptor protein to the cytoplasmic domain of ROBO receptors which in turn regulates cell motility by modulating the actin and microtubule cytoskeleton [40]. Recently, SLIT2 has been found to promote microglia/macrophage chemotaxis (via ROBO1/2 induced PI3Kγ activation) and polarization, and its expression to increase with malignant progression and correlate with poor survival and immunosuppression [41]. It is worth noting that SLIT2 knockdown in tumour cells inhibits mouse macrophage invasion [41].

3.6. Lethal-7 microRNAs (Let-7 miRNA)

The family of let-7 microRNAs, which share an evolutionarily conserved sequence, are highly expressed in the brain [42]. Recent studies have indicated that let-7 microRNAs are involved in cancer initiation and brain tumour progression [42]. Moreover, it is known that Toll-like receptors are pattern recognition receptors found on microglia that detect pathogen- and host-derived factors such as miRNAs [42]. Let-7 miRNA, specifically ones carrying the core sequence motif UUGU, can activate microglial and BMDM Toll-like receptor (TLR) 7 and induce TNF-α production which might lead to suppression of glioma growth [43]. It is worth noting that selective groups of let-7 miRNAs regulate the expression of antigen-presenting molecules in the CNS. These includes let-7b and let-7e miRNAs which stimulate up-regulation of MHC I and ICAM1 (CD54) through TLR7 signalling [43]. Of note, MHC I and ICAM1 are critically important for the communication between innate and adaptive immune cells and activation of T cell-mediated cytotoxic responses [43]. Interestingly, let-7 miRNA oligoribonucleotides that lack the GU-rich core motif may act as a chemoattractant for microglial cells in glioma [43]. Furthermore, the let-7 miRNAs induced TLR-7 activation is observed in both neonatal and adult microglia/BMDMs [43]. Thus, it is hypothesised that let-7 miRNAs can potentially shift microglia towards an “anti-tumour” phenotype and enhance the efficacy of immunotherapies.

4. Glioblastoma Weakens Microglia/Macrophage Defence Mechanisms

4.1. Molecules Involved in the Differentiation of Monocytes

4.1.1. CD14 and MicroRNA-146 (miRNA-146)

Numerous studies have demonstrated that GBMs are infiltrated by immune cells, and by microglia and monocyte-derived macrophages in particular [44]. It has been shown that an increased number of microglia and brain macrophages is associated with a higher WHO grade in gliomas [45]. The WHO classification is essentially a malignancy scale that helps clinicians predict a patient’s disease course (prognostication). Tumors are graded benign (grade 1) or malignant, and there are different grades of malignancy expressed as “grade 2–4” with 4 being worst (shortest expected survival time) [46]. In order to avoid confusion, a grade 2 glioma will progress and cannot be considered benign although it is not fully malignant yet. Gabrusiewicz et al. recently reported that the number of CD14+ monocytes is increased in the blood of GBM patients [47]. Using whole-genome expression profiling, the authors also observed that GBM-associated myeloid cells do not exist in distinct polarized M1 and M2 states. Moreover, gene set enrichment analysis revealed MYC and E2F transcriptional regulation in CD14+ cells. Interestingly, Gabrusiewicz et al. also pointed out that miRNA-146 may play a role in pro-inflammatory macrophages; its expression was significantly suppressed in GBM-infiltrating CD14+ cells. Strikingly, a previouly mentioned glioma-derived molecule, Spp1 was also highly expressed in GBM-infiltrating CD14+ BMDM [47].

4.1.2. Macrophage Migration Inhibitory Factor (MIF)-CD74

MIF is a molecule that is highly conserved across species suggesting it has a role in fundamental biological processes [48]. Accumulating evidence suggests that MIF is expressed by immune cells in various cancers including breast and lung cancer [48]. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of bone marrow-derived progenitor cells that consist of monocytic (M-MDSC) and granulocytic (G-MDSC) subsets which exhibit potent immunosuppressive activity. They interfere with the cytotoxic functions of natural killer (NK) cells and T lymphocytes in tumours including GBM [49][50]. A recent experimental study by Alban and colleagues [51] has found that the monocytic subset of myeloid-derived suppressor cells (M-MDSCs) expresses high levels of CD74 in the presence of glioma-derived macrophage migration inhibitory factor (MIF) and glioma cells. Using a syngeneic murine model, the authors further described that disruption of the MIF-CD74 pathway using Ibudilast minimises downstream activation of CCL2 (MCP-1). CCL2 was previously shown to have a critical role in driving recruitment of monocytes and expansion of MDSCs [52][53]. Of note, MIF is also capable of mediating signalling via non-cognate receptors such as CXCR2, CXCR4, and CXCR7 [51]. Importantly, activation of microglial CD74 weakens the microglial defense against glioma cells [54]. Furthermore, MIF expression is significantly increased in malignant glioma and interferon (IFN)-γ secretion by microglia is inhibited by MIF-CD74 signalling [54].

4.2. GBM-Induced Impediment of Microglia/BMDM Phagocytic Activity

4.2.1. P-Selectin (SELP)-P-Selectin Glycoprotein Ligand-1 (PSGL1)

SELP is a well-known adhesion molecule involved in leukocyte rolling and recruitment [55]. It is now evident that SELP and its ligand PSGL-1 are involved in the metastatic spread of melanoma and colon cancer [56]. Recently, a mechanism has been proposed by which SELP-PSGL1 mediate GBM progression influencing microglia/macrophage phenotype [57]. The authors found that recombinant SELP reduced the phagocytic activity of microglia/BMDM, decreased their expression of inducible nitric oxide synthase (iNOS) and release of nitric oxide (NO) while increasing expression of IL-10 and TGF-β. It is worth noting that following exposure to soluble SELP (sSELP), a positive feedback loop causes overexpression of SELP and PSGL-1 by GBM and microglia cells [57]. On the flip side, expression of actin nucleation promoting factor wasla by microglial cells was found to revive microglial phagocytotic activity and slow down GBM progression in zebrafish [58].

4.2.2. CD47-SIRPα Anti-Phagocytic Axis

A recent experimental study by Hutter and co-workers has indicated that tumour-associated microglia are capable of tumour cell phagocytosis in vivo if the immune evasion of tumour cells is blocked by a humanized anti-CD47 monoclonal antibody [59]. Notably, Li et al. have shown that CD47 is expressed by human and mouse glioma cell lines and that positive cells have many characteristics of cancer stem cells [60]. The view is also supported by Hu et al. [61] who report that overexpression of the LRIG2 (Leucine Rich Repeats And Immunoglobulin Like Domains 2) gene in GBM cells induces upregulation of CD47 and activation of the CD47-SIRPα anti-phagocytic axis [62]. Further experiments revealed that soluble LRIG (sLRIG) induces recruitment of BMDM that exhibit an immunosuppressive phenotype and also express high levels of CD47 receptor, SIRPα [61]. As expected, knockdown of LRIG2/sLRIG2 in GL261 (murine GBM) cells interferes with the activation of the CD47–SIRPα anti-phagocytic axis and enhances BMDM-mediated phagocytosis of GBM cells and suppresses GBM progression [61]. This is in keeping with the results of a xenograft study by Gholamin et al. showing ubiquitous expression of CD47 in paediatric GBM and diffuse midline glioma [62]. Blockage of the anti-phagocytic CD47-SIRPα axis using an anti-CD47 antibody, Hu5F9-G4, strongly induced BMDM-mediated phagocytosis of glioma cells, and mice treated with Hu5F9-G4 demonstrated significant longer survival [62]. It is worth noting that the “don’t eat me” signal mediated by the CD47-SIRPα axis [63] also protects synapses from non-specific pruning during development and disease. Accordingly, CD47 deficiency in mice leads to reduced synaptic density resulting from excessive pruning by microglia [64]. Loss of microglial SIRPα has a similar effect in preclinical models of neurodegeneration [65]. Thus, the CD47-SIRPα axis may deserve special attention in the context of cognitive deficits of brain tumour patients even though Li et al. were unable to detect damage to neurons and astrocytes in a treatment model [60].

4.3. GBM-Induced Immune Tolerance Involving Microglia/BMDM

The interactions between tumour-associated microglia/brain macrophages and T cells may lead to T cell malfunction and diminished T-cell mediated anti-tumour responses [66]. By analysing RNAs found in extracellular vesicles (EVs) derived from microglia that had interacted with GBM, Maas et al. [67] recently found that GBM-interacting microglia down-regulate genes involved in the detection of tumour cells (sialic acid-binding immunoglobulin-like lectin-H (Siglec-H), CD33 and GPR34) and tumour-derived metabolic by-products (Gpr183, Adora3, Il6Ra, Cx3cr1, P2ry12, P2ry13, Csf1r, and Csf3r) [67]. In contrast, levels of CD274 (PD-L1) and PD-L2 transcripts are elevated in GBM-interacting microglia, suggesting that genes involved in immunologic tolerance are up-regulated in microglia by GBM contact, resulting in indirect inhibition of anti-tumour functions of T cells [68]. Interestingly, the authors further demonstrated that GBM-interacting microglia show up-regulated expression of phagocytic receptors (Cd93, Msr1, Cd36, Olr1, Megf10, Clec7a, Scarf1) and extracellular matrix (ECM) degrading enzymes such as Mmp14 [67]. A recent study supports the invasion-facilitating role of microglial cells by describing that glial cell line-derived neurotrophic factor (GDNF), a chemoattractant of microglia [69], stimulates the production of microglia-derived MMP9 and MMP14 in neonatal mice [70]. Huang et al. further indicated that GDNF induced up-regulation of microglial TLR1 and TLR2 and that the activation of TLR2 can increase expression of microglial MMP9 and MMP14 [70]. In addition to stimulating expression of ECM degrading enzymes, the activation of TLR2 also inhibited expression of MHC class II by microglial cells via loss of histone H3 acetylation at the master regulator of MHC class II molecule transcription, Ciita (Class II Major Histocompatibility Complex Transactivator). Accordingly, inhibited MHC II expression impedes CD4+ T cell activation and proliferation which weakens T-cell dependent anti-tumour responses [71]. Expression of the GBM-associated microglial phenotype appears to be mediated by EVs, a view that is supported by animal experiments demonstrating that intracranial injection of glioma-derived EVs in healthy mice results in similarly modified transcription [67]. Recently, Mirzai and Wong [5] have reviewed microglia-T cell communication and pointed out that the synthesis of immunosuppressive cytokines such as TGF-β and IL-10 is increased as a consequence of their interaction. In addition to the release of immunosuppressive cytokines, Acod1 (aconitate decarboxylase 1) has been identified as a gene that is involved in the regulation and subsequent adjustment of the microglia/macrophage phenotype during GBM progression [72]. These findings are in line with the view that GBM alters gene transcription in microglia, supporting tumour invasion and migration while microglia remove necrotic debris and digested ECM in the TME. It is also worth mentioning that CXCL14 has been proposed as an important determinant of the glioma immune microenvironment where it is thought to promote activated CD8+ T cell chemotaxis which appears to prolong survival [73]. Interestingly, pleomorphic xanthoastrocytoma (PXA) shows increased CXCL14 secretion and contains a higher number of activated cytotoxic CD8+ T cells, increased expression of MHC class I and other genes associated with antigen presentation and processing as well as a higher number of AIF1 (Iba1)+ immunoreactive microglia/macrophages when compared to IDH-mutant astrocytoma [73]. Blockage of Spp1 not only reduces recruitment of macrophages but also renders GBM cells more sensitive to direct CD8+ T cell cytotoxicity [30]. Inhibition of MIF-CD74 interaction also leads to the expansion and activation of CD8+ T cells [51].

5. Microglial/BMDM-Derived Factors Supporting Glioma Progression

5.1. C-C Motif Chemokine Ligand 5 (CCL5)/Akt/Calcium (Ca2+)/Calmodulin-Dependent Protein Kinase II Phosphorylation (p-CaMKII) Pathway

CCL5 is an inflammatory cytokine secreted by multiple cell types, including endothelial cells, monocytes, macrophages and NK cells [74]. Moreover, CCL5 is involved in tumour growth and cell migration in various cancers including glioma [74]. Glioma cells that have been stimulated with CCL5 show increased intracellular calcium levels and elevated Akt (p-Akt) and Ca2+/calmodulin-dependent protein kinase II phosphorylation (p-CaMKII) in a time- and dose-dependent manner. Increased intracellular calcium levels and p-CaMKII lead to upregulated expression of calcium-dependent MMP2 in glioma cells [75]; MMP2 has been previously associated with GBM cell migration and invasion [76]. In addition to the invasion-promoting role of CCL5, Wu et al. also demonstrated that glioma cells exhibit a strong affinity for glioma-associated microglia/macrophages (GAMs), specifically GAMs that have been activated by Granulocyte-macrophage colony-stimulating factor (GM-CSF). The authors even use the term “homing”. This observation fits with findings showing that conditioned media derived from GM-CSF activated GAMs contain significantly higher concentrations of CCL5 [75]. Moreover, a more recent study has shown that expression of CD11a by microglia may play an important role in the production of glioma derived CCL5 [77]. On the flip side, small interfering RNA silencing of CaMKII resulted in inhibition of CCL5-mediated glioma invasion [75]. Furthermore, downregulated expression of microglial CCL5 and CCR2 in athymic mice showed impaired engraftment of Nf1 optic low grade glioma stem cells [78]. Another study has shown that Na+/H+ exchanger isoform 1 (NHE1), a major interaction partner of calmodulin, stimulates microglial release of soluble factors leading to enhanced glioma proliferation and invasion [79] whereas blockage of NHE1 improves glioma tumour immunity by restoring mitochondrial OXPHOS (oxidative phosphorylation) function in myeloid cells [80]. Furthermore, Venkataramani et al. [81] have found that neural stimulation induces higher intracellular calcium level in GBM cells resulting in de novo formation of GBM microtubes and increased tumour invasiveness.

5.2. Stress Induced Phosphoprotein 1 (STIP1/STI1)

The co-chaperone STIP1 (STI1), a ligand of the cellular prion protein [82], has been demonstrated to participate in the survival and differentiation of neuronal cells [83]. STIP1 is highly expressed in glioma cells [84]. Strikingly, increased levels of STIP1 are also noted in microglia/macrophages as glioma progresses [84]. Furthermore, a significant upregulation of STIP1 expression is observed in glioma-infiltrating macrophages [84]. Therefore, STIP1 falls into the category of “Janus” genes. They represent promising therapeutic targets.

6. Isocitrate Dehydrogenase (IDH) Mutation Status Influences Glioblastoma Microglia/Macrophage Tissue Phenotype

Large-scale histological and molecular genetic studies have demonstrated that IDH-wildtype (IDH-WT) GBM is the most common and aggressive glioma subtype. In comparison, glioma patients that carry an IDH1/2 mutation (IDH-mutation) show comparatively longer survival times [46]. These differences are reflected in the new (2021) WHO classification of CNS tumours by the creation of separate categories for these tumour types [46]. Importantly, the observation of co-expression of IDH1R132H and the macrophage marker CD68 in human GBM specimens by Cao et al. stimulates renewed interest in the possible existence of TAM-GBM cell hybrids [85].

6.1. Microglia/Macrophages in IDH-Mutant Astrocytoma (Grade 4) and IDH-Wildtype GBM

By leveraging single-cell transcriptomics, Liu et al. [86] have pointed out that the presence of a higher number of microglia/macrophages correlates with a worse prognosis in IDH-wildtype (IDH-WT) GBM. With respect to IDH-WT GBM, Klemm et al. [87] found that there is a difference in the ratio between microglia and BMDM between the different high grade glioma subtypes with microglia being more abundant in IDH-mutant gliomas [87]. In line with findings by Liu and Klemm et al., Poon and colleagues [88] have observed that there are strikingly fewer microglia and macrophages in grade 4 IDH-mutant astrocytoma than in IDH-WT GBM. Interestingly, these cells show a pro-inflammatory signature in IDH-mutant astrocytoma. In contrast, a macrophage anti-inflammatory phenotype (upregulation of FCER1G and TYROBP genes) was found in IDH-WT GBM [88]. It has been demonstrated that FCER1G and TYROBP genes play a key role in the CSF1R pathway [89] and are essential for the differentiation of microglia and macrophages [90]. Work using experimental animals suggests that the immunosuppressive microenvironment of IDH1-WT GBM can be influenced by blocking Wnt signalling between microglia and cancer cells [91].

6.2. SET Domain Containing 2, Histone Lysine Methyltransferase (SETD2)

A recent scRNA-seq analysis study has reported that NLR family pyrin domain containing 1 (NLRP1) inflammasome mediated IL-1β expression by microglia induces proliferation of GBM cells [86]. Microglia in mutant SETD2 (SETD2-mut)/IDH-WT GBM exhibit pro-inflammatory and proliferative phenotypes probably through stimulation of glioma-derived TGF-β1 expression via the apolipoprotein E (ApoE)-mediated NLRP1 inflammasome [86]. Of note, TGF-β1/TGF-β receptor I (TbRI) depletion might be used to reduce the density of microglia and to suppress tumour growth [86].

6.3. Intercellular Adhesion Molecule 1 (ICAM1), Lysosomal Associated Membrane Protein 1 (LAMP1) and Transmembrane Protein 119 (TMEM119)

A xenograft study revealed that introduction of a heterozygous IDH1R132H mutation into glioma cells has an effect on glioma-associated macrophages which are stimulated to express a more phagocytic, anti-tumour phenotype [92]. These authors further suggested that the underlying mechanism appears to involve ICAM1 [92]. Mutant IDH1 (IDH1-mut) glioma cells downregulate ICAM1 via ICAM1 promoter methylation resulting in an increased expression of LAMP1 (CD107a), a lysosome-associated membrane protein which has a key role in the formation of phagolysosomes [93]. The authors also found that the microglia marker TMEM119 was decreased significantly in IDH1R132H mutant tumour implants [92].

6.4. C-C Motif Chemokine Ligand 18 (CCL18)/Chemokine (C-C Motif) Receptor 8 (CCR8)/Acid Phosphatase 5 (ACP5)/AKT1 Substrate 1 (AKT1S1/PRAS40)/Akt Pathway

CCL18 is a member of the CC chemokine family and is predominantly secreted by myeloid cells such as monocytes, macrophages and dendritic cells. Recent studies revealed that CCL18 plays a pivotal role in the epithelial-mesenchymal transition in pancreatic and breast cancer [94][95]. Huang et al. have used an ex vivo model of induced pluripotent stem cell (iPSC)-derived human microglia/macrophages and shown that the cells upregulate CCL18 and induce glioma cell growth and invasion via the CCR8/ACP5/AKT1S1 (PRAS40)/Akt pathway [96]. Importantly, an increased expression of CCL18 is inversely correlated with survival time in primary and recurrent IDH-WT GBM patients [96].

6.5. ATP Binding Cassette Subfamily A Member 1 (ABCA1)

Patients affected by IDH1 mutant high-grade glioma and IDH-WT GBM, respectively, show distinct clinical features and prognostic differences. Wildtype IDH1 and IDH2 catalyse the conversion of isocitrate to alpha-ketoglutarate (α-KG), whereas the IDH1 and IDH2 mutant enzymes exhibits a neomorphic function catalysing the reduction of α-KG to oncometabolite D-2-hydroxyglutarate (D-2HG) [97]. In a hypoxic environment, the IDH1-dependent pathway is significantly up-regulated and facilitates reductive glutamine metabolism which is used in lipogenesis and maintains the proliferation of GBM cells [97][98]. By utilising annotation analysis of metabolism-related genes, Wang et al. suggested that macrophages in IDH-WT GBMs significantly increase expression of ABCA1 [99]. The ABCA1 gene encodes a membrane-associated protein that uses cholesterol as its substrate and induces cholesterol efflux in the cellular lipid removal pathway [99][100][101]. Interestingly, down-regulation of ABCA1 expression can restore a pro-inflammatory phenotype in tumour-associated macrophages and may provide a therapeutic target for IDH-WT GBM [99].

7. Exosomes, Extracellular Vesicles and MicroRNAs in Glioma Progression

Exosomes are small membrane vesicles that are crucial for intercellular communication [102]. Recently, tumour-derived exosomes have been found to play an essential role in the immunosuppressive effects on immune cells by delivering several types of proteins and non-coding RNAs such as miRNAs, long noncoding RNAs and circular RNAs (circRNAs) [102][103]. A number of studies are now suggesting that a hypoxic tumour environment can modify the genetic content within exosomes and modulate the cell functions of recipient cells [104][105].

7.1. Interleukin-6 (IL-6) and MicroRNA-155-3p (miR-155-3p)

Various cell types in the TME of cancers release IL-6, leading to the activation of the IL-6/JAK/STAT3 pathway in both tumour cells and tumour-associated immune cells, which in turn promotes tumour cell proliferation, invasiveness and metastasis [106]. MiR-155-3p is involved in tumorigenesis and is highly expressed in several cancers, including breast cancer and glioma [107][108]. A recent experimental study by Xu et al. [109] reported that exosomes derived from human GBM cell lines that had been subjected to hypoxia stimulated autophagy in macrophages (cell lines). Elevated IL-6 and miR-155-3p levels in the exosomes appeared to be responsible for the effect. Further Western blot analysis revealed that IL-6 triggers autophagy in macrophages by activating STAT3 signalling. Using flow cytometry and ELISA, the authors also found that increased IL-6 and miR-155-3p in the treated exosomes significantly induced CD163 and IL-10 expression in macrophages [109]. Taken together, IL-6 and miR-155-3p delivered by “hypoxic” exosomes derived from human GBM cells drive macrophages towards an immunosuppressive phenotype which supports glioma proliferation and migration.

7.2. MicroRNA-1246 (miR-1246)

Qian et al. [110] have demonstrated that miR-1246 contained within “hypoxic” glioma-derived exosomes (H-GDEs) is capable of inducing an immunosuppressive phenotype in macrophages (increased CD163, IL-10, IL1RA, TGFβ1 and CCL2 [111] expression, and significantly decreased TNF-α expression) [110]. In addition to its immunosuppressive function, further analysis revealed that miR-1246 also binds to the 3′-untranslated region of Telomeric repeat-binding factor 2-interacting protein 1 (TERF2IP) leading to inhibition of its expression as well as induction of an immunosuppressive phenotype in macrophages via STAT3 and NF-κB [110]. Activation of STAT3 and inhibition of the NF-κB pathway which foster an immunosuppressive TME also promote the proliferation, migration and invasion of glioma cells in vitro as well as in vivo [112]. Interestingly, abundant expression of miR-1246 is found in the CSF (cerebrospinal fluid) of GBM patients and significantly reduced following surgical resection [110].

7.3. Circ_0012381, Arginine Deprivation

Since radiated GBM cells release exosomal circ_0012381 which induces M2 polarization of microglia leading to better growth of GBM via the CCL2/CCR2 axis, Zhang et al. [113] suggested that inhibition of exosome secretion might represent a potential therapeutic strategy to improve the efficacy of radiotherapy in GBM patients. Arginine deprivation may also have a positive therapeutic effect in a subset of cases [114].

7.4. MicroRNA as a Potential Therapeutic Tool for Targeting Glioma

Extracellular vesicles (EVs) are released by GSCs and used for their communication with microglial cells and brain macrophages. For instance, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) modulates the inflammatory response of microglia after LPS stimulation through regulating the miR-129-5p/HMGB1 axis [115]. Exposure of microglia to EVs released by hyperbaric oxygen-treated GBM cells up-regulates the expression of pro-inflammatory cytokines IL-1β, IL-6 and STAT1 and down-regulates the anti-inflammatory cytokine PPARγ [116]. This finding was further corroborated by a recent study by Wang et al. [117] who proposed that via EVs, Cavin1 overexpressing glioma cells exert a general activating effect on microglia/macrophages. In turn, microglia-derived EVs modify tumour cell metabolism and enhance glutamate clearance through miR-124 leading to reduced glioma growth [118]. These findings are significant because microRNA-loaded EVs have been proposed as the basis for a new type of glioma therapy as miR-124 delivery exerts synergistic anti-tumour effects by inhibiting M2 microglial polarization and suppressing the growth of human GBM [119].

This entry is adapted from the peer-reviewed paper 10.3390/ijms232415612

References

  1. Graeber, M.B.; Scheithauer, B.W.; Kreutzberg, G.W. Microglia in brain tumors. Glia 2002, 40, 252–259.
  2. Wang, G.; Zhong, K.; Wang, Z.; Zhang, Z.; Tang, X.; Tong, A.; Zhou, L. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities. Front. Immunol. 2022, 13, 964898.
  3. Xia, H.; Deng, L.; Meng, S.; Liu, X.; Zheng, C. Single-Cell Transcriptome Profiling Signatures and Alterations of Microglia Associated With Glioblastoma Associate Microglia Contribution to Tumor Formation. Pathol. Oncol. Res. 2022, 28, 1610067.
  4. Keane, L.; Cheray, M.; Blomgren, K.; Joseph, B. Multifaceted microglia—key players in primary brain tumour heterogeneity. Nat. Rev. Neurol. 2021, 17, 243–259.
  5. Mirzaei, R.; Yong, V.W. Microglia–T cell conversations in brain cancer progression. Trends Mol. Med. 2022, 28, 951–963.
  6. Müller, A.; Brandenburg, S.; Turkowski, K.; Müller, S.; Vajkoczy, P. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int. J. Cancer 2015, 137, 278–288.
  7. Müller, S.; Kohanbash, G.; Liu, S.J.; Alvarado, B.; Carrera, D.; Bhaduri, A.; Watchmaker, P.B.; Yagnik, G.; Di Lullo, E.; Malatesta, M. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017, 18, 1–14.
  8. Pires-Afonso, Y.; Niclou, S.P.; Michelucci, A. Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma. Int. J. Mol. Sci. 2020, 21, 689.
  9. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69–82.
  10. Heddleston, J.M.; Li, Z.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8, 3274–3284.
  11. Zeiner, P.S.; Preusse, C.; Golebiewska, A.; Zinke, J.; Iriondo, A.; Muller, A.; Kaoma, T.; Filipski, K.; Müller-Eschner, M.; Bernatz, S. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. Brain Pathol. 2019, 29, 513–529.
  12. Yi, L.; Xiao, H.; Xu, M.; Ye, X.; Hu, J.; Li, F.; Li, M.; Luo, C.; Yu, S.; Bian, X. Glioma-initiating cells: A predominant role in microglia/macrophages tropism to glioma. J. Neuroimmunol. 2011, 232, 75–82.
  13. Ye, X.-Z.; Xu, S.-L.; Xin, Y.-H.; Yu, S.-C.; Ping, Y.-F.; Chen, L.; Xiao, H.-L.; Wang, B.; Yi, L.; Wang, Q.-L. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J. Immunol. 2012, 189, 444–453.
  14. Sørensen, M.D.; Dahlrot, R.H.; Boldt, H.B.; Hansen, S.; Kristensen, B.W. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Neuropathol. Appl. Neurobiol. 2018, 44, 185–206.
  15. Yuan, Y.; Zhao, Q.; Zhao, S.; Zhang, P.; Zhao, H.; Li, Z.; Du, Y.; Tian, X.; Lu, J. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma. Cancer Med. 2019, 8, 3811–3821.
  16. Binnewies, M.; Roberts, E.W.; Kersten, K.; Chan, V.; Fearon, D.F.; Merad, M.; Coussens, L.M.; Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Hedrick, C.C. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018, 24, 541–550.
  17. Zhang, H.; Zhang, W.; Sun, X.; Dang, R.; Zhou, R.; Bai, H.; Ben, J.; Zhu, X.; Zhang, Y.; Yang, Q. Class A1 scavenger receptor modulates glioma progression by regulating M2-like tumor-associated macrophage polarization. Oncotarget 2016, 7, 50099.
  18. Sørensen, M.D.; Kristensen, B.W. Tumour-associated CD204+ microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin-6-enriched inflammatory profile in glioblastoma. Neuropathol. Appl. Neurobiol. 2022, 48, e12772.
  19. Woolf, Z.; Swanson, M.E.; Smyth, L.C.; Mee, E.W.; Schweder, P.; Heppner, P.; Kim, B.J.; Turner, C.; Oldfield, R.L.; Curtis, M.A. Single-cell image analysis reveals a protective role for microglia in glioblastoma. Neuro-Oncol. Adv. 2021, 3, vdab031.
  20. Milior, G.; Morin-Brureau, M.; Chali, F.; Le Duigou, C.; Savary, E.; Huberfeld, G.; Rouach, N.; Pallud, J.; Capelle, L.; Navarro, V.; et al. Distinct P2Y Receptors Mediate Extension and Retraction of Microglial Processes in Epileptic and Peritumoral Human Tissue. J. Neurosci. 2020, 40, 1373–1388.
  21. Saavedra-López, E.; Roig-Martínez, M.; Cribaro, G.P.; Casanova, P.V.; Gallego, J.M.; Pérez-Vallés, A.; Barcia, C. Phagocytic glioblastoma-associated microglia and macrophages populate invading pseudopalisades. Brain Commun. 2020, 2, fcz043.
  22. Hide, T.; Komohara, Y.; Miyasato, Y.; Nakamura, H.; Makino, K.; Takeya, M.; Kuratsu, J.-I.; Mukasa, A.; Yano, S. Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. EBioMedicine 2018, 30, 94–104.
  23. Caponegro, M.D.; Oh, K.; Madeira, M.M.; Radin, D.; Sterge, N.; Tayyab, M.; Moffitt, R.A.; Tsirka, S.E. A distinct microglial subset at the tumor-stroma interface of glioma. Glia 2021, 69, 1767–1781.
  24. Dugandzija, T.; Drljaca, J.; Bulajic, D.; Isakovic, A.; Stilinovic, N.; Sekulic, S.; Capo, I. Hallmarks of tumor-associated microglia response to experimental U87 human glioblastoma xenograft. Tissue Cell 2021, 72, 101557.
  25. Sharpe, M.A.; Baskin, D.S.; Jenson, A.V.; Baskin, A.M. Hijacking Sexual Immuno-Privilege in GBM-An Immuno-Evasion Strategy. Int. J. Mol. Sci. 2021, 22, 983.
  26. Turaga, S.M.; Silver, D.J.; Bayik, D.; Paouri, E.; Peng, S.; Lauko, A.; Alban, T.J.; Borjini, N.; Stanko, S.; Naik, U.P.; et al. JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro Oncol. 2020, 22, 1591–1601.
  27. Ochocka, N.; Segit, P.; Walentynowicz, K.A.; Wojnicki, K.; Cyranowski, S.; Swatler, J.; Mieczkowski, J.; Kaminska, B. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat. Commun. 2021, 12, 1–14.
  28. Wai, P.Y.; Kuo, P.C. The role of osteopontin in tumor metastasis. J. Surg. Res. 2004, 121, 228–241.
  29. Martinez-Lage, M.; Lynch, T.M.; Bi, Y.; Cocito, C.; Way, G.P.; Pal, S.; Haller, J.; Yan, R.E.; Ziober, A.; Nguyen, A.; et al. Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol. Commun. 2019, 7, 203.
  30. Wei, J.; Marisetty, A.; Schrand, B.; Gabrusiewicz, K.; Hashimoto, Y.; Ott, M.; Grami, Z.; Kong, L.-Y.; Ling, X.; Caruso, H. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J. Clin. Investig. 2019, 129, 137–149.
  31. Ellert-Miklaszewska, A.; Wisniewski, P.; Kijewska, M.; Gajdanowicz, P.; Pszczolkowska, D.; Przanowski, P.; Dabrowski, M.; Maleszewska, M.; Kaminska, B. Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression. Oncogene 2016, 35, 6366–6377.
  32. Bao, S.; Ouyang, G.; Bai, X.; Huang, Z.; Ma, C.; Liu, M.; Shao, R.; Anderson, R.M.; Rich, J.N.; Wang, X.-F. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5, 329–339.
  33. Malanchi, I.; Santamaria-Martínez, A.; Susanto, E.; Peng, H.; Lehr, H.-A.; Delaloye, J.-F.; Huelsken, J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481, 85–89.
  34. Zhou, W.; Ke, S.Q.; Huang, Z.; Flavahan, W.; Fang, X.; Paul, J.; Wu, L.; Sloan, A.E.; McLendon, R.E.; Li, X. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 2015, 17, 170–182.
  35. Guo, X.; Xue, H.; Shao, Q.; Wang, J.; Guo, X.; Chen, X.; Zhang, J.; Xu, S.; Li, T.; Zhang, P. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget 2016, 7, 80521.
  36. Shen, J.-X.; Liu, J.; Zhang, G.-J. Interleukin-33 in malignancies: Friends or foes? Front. Immunol. 2018, 9, 3051.
  37. De Boeck, A.; Ahn, B.Y.; D’Mello, C.; Lun, X.; Menon, S.V.; Alshehri, M.M.; Szulzewsky, F.; Shen, Y.; Khan, L.; Dang, N.H. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nat. Commun. 2020, 11, 1–24.
  38. Carriere, V.; Roussel, L.; Ortega, N.; Lacorre, D.-A.; Americh, L.; Aguilar, L.; Bouche, G.; Girard, J.-P. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 2007, 104, 282–287.
  39. Zhang, Q.; Wang, J.; Yao, X.; Wu, S.; Tian, W.; Gan, C.; Wan, X.; You, C.; Hu, F.; Zhang, S. Programmed cell death 10 mediated cxcl2-cxcr2 signaling in regulating tumor-associated microglia/macrophages recruitment in glioblastoma. Front. Immunol. 2021, 12, 637053.
  40. Blockus, H.; Chédotal, A. Slit-robo signaling. Development 2016, 143, 3037–3044.
  41. Geraldo, L.H.; Xu, Y.; Jacob, L.; Pibouin-Fragner, L.; Rao, R.; Maissa, N.; Verreault, M.; Lemaire, N.; Knosp, C.; Lesaffre, C. SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. J. Clin. Investig. 2021, 131, e141083.
  42. Gilles, M.-E.; Slack, F.J. Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin. Ther. Targets 2018, 22, 929–939.
  43. Buonfiglioli, A.; Efe, I.E.; Guneykaya, D.; Ivanov, A.; Huang, Y.; Orlowski, E.; Krüger, C.; Deisz, R.A.; Markovic, D.; Flüh, C. let-7 MicroRNAs regulate microglial function and suppress glioma growth through toll-like receptor 7. Cell Rep. 2019, 29, 3460–3471.e3467.
  44. Kettenmann, H.; Hanisch, U.-K.; Noda, M.; Verkhratsky, A. Physiology of microglia. Physiol. Rev. 2011, 91, 461–553.
  45. Roggendorf, W.; Strupp, S.; Paulus, W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 1996, 92, 288–293.
  46. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. Lyon (France): International Agency for Research on Cancer: 2021; WHO Classification of Tumours Series, 5th ed.; Volume 6. Available online: https://tumourclassification.iarc.who.int/chapters/45 (accessed on 11 October 2022).
  47. Gabrusiewicz, K.; Rodriguez, B.; Wei, J.; Hashimoto, Y.; Healy, L.M.; Maiti, S.N.; Thomas, G.; Zhou, S.; Wang, Q.; Elakkad, A. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 2016, 1, e85841.
  48. Calandra, T.; Roger, T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat. Rev. Immunol. 2003, 3, 791–800.
  49. Lindau, D.; Gielen, P.; Kroesen, M.; Wesseling, P.; Adema, G.J. The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013, 138, 105–115.
  50. Raychaudhuri, B.; Rayman, P.; Ireland, J.; Ko, J.; Rini, B.; Borden, E.C.; Garcia, J.; Vogelbaum, M.A.; Finke, J. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncol. 2011, 13, 591–599.
  51. Alban, T.J.; Bayik, D.; Otvos, B.; Rabljenovic, A.; Leng, L.; Jia-Shiun, L.; Roversi, G.; Lauko, A.; Momin, A.A.; Mohammadi, A.M. Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression. Front. Immunol. 2020, 11, 1191.
  52. Hoi, A.Y.; Hickey, M.J.; Hall, P.; Yamana, J.; O’Sullivan, K.M.; Santos, L.L.; James, W.G.; Kitching, A.R.; Morand, E.F. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J. Immunol. 2006, 177, 5687–5696.
  53. Leng, L.; Chen, L.; Fan, J.; Greven, D.; Arjona, A.; Du, X.; Austin, D.; Kashgarian, M.; Yin, Z.; Huang, X.R. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J. Immunol. 2011, 186, 527–538.
  54. Ghoochani, A.; Schwarz, M.A.; Yakubov, E.; Engelhorn, T.; Doerfler, A.; Buchfelder, M.; Bucala, R.; Savaskan, N.E.; Eyüpoglu, I.Y. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene 2016, 35, 6246–6261.
  55. McEver, R.P. Selectins: Initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc. Res. 2015, 107, 331–339.
  56. Läubli, H.; Borsig, L. Selectins promote tumor metastasis. In Seminars in Cancer Biology; Academic Press: Cambridge, MA, USA, 2010; pp. 169–177.
  57. Yeini, E.; Ofek, P.; Pozzi, S.; Albeck, N.; Ben-Shushan, D.; Tiram, G.; Golan, S.; Kleiner, R.; Sheinin, R.; Israeli Dangoor, S.; et al. P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression. Nat. Commun. 2021, 12, 1–12.
  58. Mazzolini, J.; Le Clerc, S.; Morisse, G.; Coulonges, C.; Zagury, J.F.; Sieger, D. Wasl is crucial to maintain microglial core activities during glioblastoma initiation stages. Glia 2022, 70, 1027–1051.
  59. Hutter, G.; Theruvath, J.; Graef, C.M.; Zhang, M.; Schoen, M.K.; Manz, E.M.; Bennett, M.L.; Olson, A.; Azad, T.D.; Sinha, R.; et al. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. Proc. Natl. Acad. Sci. USA 2019, 116, 997–1006.
  60. Li, F.; Lv, B.; Liu, Y.; Hua, T.; Han, J.; Sun, C.; Xu, L.; Zhang, Z.; Feng, Z.; Cai, Y.; et al. Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. OncoImmunology 2018, 7, e1391973.
  61. Hu, J.; Dong, F.; He, Y.; Xia, X.; Cheng, F.; Chen, S.; Hou, X.; Zhang, P.; Liu, G.; Li, Y. LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization. J. ImmunoTherapy Cancer 2022, 10, e004452.
  62. Gholamin, S.; Mitra, S.S.; Feroze, A.H.; Liu, J.; Kahn, S.A.; Zhang, M.; Esparza, R.; Richard, C.; Ramaswamy, V.; Remke, M. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med. 2017, 9, eaaf2968.
  63. Chao, M.P.; Jaiswal, S.; Weissman-Tsukamoto, R.; Alizadeh, A.A.; Gentles, A.J.; Volkmer, J.; Weiskopf, K.; Willingham, S.B.; Raveh, T.; Park, C.Y. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2010, 2, 63ra94.
  64. Lehrman, E.K.; Wilton, D.K.; Litvina, E.Y.; Welsh, C.A.; Chang, S.T.; Frouin, A.; Walker, A.J.; Heller, M.D.; Umemori, H.; Chen, C. CD47 protects synapses from excess microglia-mediated pruning during development. Neuron 2018, 100, 120–134.e126.
  65. Ding, X.; Wang, J.; Huang, M.; Chen, Z.; Liu, J.; Zhang, Q.; Zhang, C.; Xiang, Y.; Zen, K.; Li, L. Loss of microglial SIRPα promotes synaptic pruning in preclinical models of neurodegeneration. Nat. Commun. 2021, 12, 1–17.
  66. Tu, S.; Lin, X.; Qiu, J.; Zhou, J.; Wang, H.; Hu, S.; Yao, Y.; Wang, Y.; Deng, Y.; Zhou, Y.; et al. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma. Front. Immunol. 2021, 12, 650105.
  67. Maas, S.L.; Abels, E.R.; Van De Haar, L.L.; Zhang, X.; Morsett, L.; Sil, S.; Guedes, J.; Sen, P.; Prabhakar, S.; Hickman, S.E. Glioblastoma hijacks microglial gene expression to support tumor growth. J. Neuroinflammation 2020, 17, 1–18.
  68. Mirzaei, R.; Sarkar, S.; Yong, V.W. T cell exhaustion in glioblastoma: Intricacies of immune checkpoints. Trends Immunol. 2017, 38, 104–115.
  69. Ku, M.-C.; Wolf, S.A.; Respondek, D.; Matyash, V.; Pohlmann, A.; Waiczies, S.; Waiczies, H.; Niendorf, T.; Synowitz, M.; Glass, R.; et al. GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis. Acta Neuropathol. 2013, 125, 609–620.
  70. Huang, Y.; Zhang, B.; Haneke, H.; Haage, V.; Lubas, M.; Yuan, Y.; Xia, P.; Motta, E.; Nanvuma, C.; Dzaye, O.; et al. Glial cell line-derived neurotrophic factor increases matrix metallopeptidase 9 and 14 expression in microglia and promotes microglia-mediated glioma progression. J. Neurosci. Res. 2021, 99, 1048–1063.
  71. Qian, J.; Luo, F.; Yang, J.; Liu, J.; Liu, R.; Wang, L.; Wang, C.; Deng, Y.; Lu, Z.; Wang, Y. TLR2 promotes glioma immune evasion by downregulating MHC class II molecules in microglia. Cancer Immunol. Res. 2018, 6, 1220–1233.
  72. Pires-Afonso, Y.; Muller, A.; Grzyb, K.; Oudin, A.; Yabo, Y.A.; Sousa, C.; Scafidi, A.; Poli, A.; Cosma, A.; Halder, R.; et al. Elucidating tumour-associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency. Mol. Oncol. 2022, 16, 3167–3191.
  73. Kumar, A.; Mohamed, E.; Tong, S.; Chen, K.; Mukherjee, J.; Lim, Y.; Wong, C.M.; Boosalis, Z.; Shai, A.; Pieper, R.O. CXCL14 promotes a robust brain tumor-associated immune response in glioma. Clin. Cancer Res. 2022, 28, 2898–2910.
  74. Lapteva, N.; Huang, X.F. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin. Biol. Ther. 2010, 10, 725–733.
  75. Yu-Ju Wu, C.; Chen, C.-H.; Lin, C.-Y.; Feng, L.-Y.; Lin, Y.-C.; Wei, K.-C.; Huang, C.-Y.; Fang, J.-Y.; Chen, P.-Y. CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2. Neuro-Oncol. 2020, 22, 253–266.
  76. Chang, L.; Zhao, D.; Liu, H.B.; Wang, Q.S.; Zhang, P.; Li, C.L.; Du, W.Z.; Wang, H.J.; Liu, X.; Zhang, Z.R. Activation of sonic hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and-9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma Corrigendum in/mmr/12/5/7815. Mol. Med. Rep. 2015, 12, 6702–6710.
  77. De Andrade Costa, A.; Chatterjee, J.; Cobb, O.; Sanapala, S.; Scheaffer, S.; Guo, X.; Dahiya, S.; Gutmann, D.H. RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. Neuro Oncol. 2022, 24, 14–26.
  78. Pan, Y.; Xiong, M.; Chen, R.; Ma, Y.; Corman, C.; Maricos, M.; Kindler, U.; Semtner, M.; Chen, Y.-H.; Dahiya, S. Athymic mice reveal a requirement for T-cell–microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth. Genes Dev. 2018, 32, 491–496.
  79. Zhu, W.; Carney, K.E.; Pigott, V.M.; Falgoust, L.M.; Clark, P.A.; Kuo, J.S.; Sun, D. Glioma-mediated microglial activation promotes glioma proliferation and migration: Roles of Na+/H+ exchanger isoform 1. Carcinogenesis 2016, 37, 839–851.
  80. Hasan, M.N.; Luo, L.; Ding, D.; Song, S.; Bhuiyan, M.I.H.; Liu, R.; Foley, L.M.; Guan, X.; Kohanbash, G.; Hitchens, T.K.; et al. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. Theranostics 2021, 11, 1295–1309.
  81. Venkataramani, V.; Yang, Y.; Schubert, M.C.; Reyhan, E.; Tetzlaff, S.K.; Wißmann, N.; Botz, M.; Soyka, S.J.; Beretta, C.A.; Pramatarov, R.L.; et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell 2022, 185, 2899–2917.e2831.
  82. Linden, R.; Martins, V.R.; Prado, M.A.; Cammarota, M.; Izquierdo, I.; Brentani, R.R. Physiology of the prion protein. Physiol. Rev. 2008, 88, 673–728.
  83. Lima, F.R.; Arantes, C.P.; Muras, A.G.; Nomizo, R.; Brentani, R.R.; Martins, V.R. Cellular prion protein expression in astrocytes modulates neuronal survival and differentiation. J. Neurochem. 2007, 103, 2164–2176.
  84. Carvalho Da Fonseca, A.C.; Wang, H.; Fan, H.; Chen, X.; Zhang, I.; Zhang, L.; Lima, F.R.S.; Badie, B. Increased expression of stress inducible protein 1 in glioma-associated microglia/macrophages. J. Neuroimmunol. 2014, 274, 71–77.
  85. Cao, M.-F.; Chen, L.; Dang, W.-Q.; Zhang, X.-C.; Zhang, X.; Shi, Y.; Yao, X.-H.; Li, Q.; Zhu, J.; Lin, Y. Hybrids by tumor-associated macrophages× glioblastoma cells entail nuclear reprogramming and glioblastoma invasion. Cancer Lett. 2019, 442, 445–452.
  86. Liu, H.; Sun, Y.; Zhang, Q.; Jin, W.; Gordon, R.E.; Zhang, Y.; Wang, J.; Sun, C.; Wang, Z.J.; Qi, X.; et al. Pro-inflammatory and proliferative microglia drive progression of glioblastoma. Cell Rep. 2021, 36, 109718.
  87. Klemm, F.; Maas, R.R.; Bowman, R.L.; Kornete, M.; Soukup, K.; Nassiri, S.; Brouland, J.-P.; Iacobuzio-Donahue, C.A.; Brennan, C.; Tabar, V. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 2020, 181, 1643–1660.e1617.
  88. Poon, C.C.; Gordon, P.M.; Liu, K.; Yang, R.; Sarkar, S.; Mirzaei, R.; Ahmad, S.T.; Hughes, M.L.; Yong, V.W.; Kelly, J.J. Differential microglia and macrophage profiles in human IDH-mutant and-wild type glioblastoma. Oncotarget 2019, 10, 3129.
  89. Forabosco, P.; Ramasamy, A.; Trabzuni, D.; Walker, R.; Smith, C.; Bras, J.; Levine, A.P.; Hardy, J.; Pocock, J.M.; Guerreiro, R. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol. Aging 2013, 34, 2699–2714.
  90. Pridans, C.; Raper, A.; Davis, G.M.; Alves, J.; Sauter, K.A.; Lefevre, L.; Regan, T.; Meek, S.; Sutherland, L.; Thomson, A.J. Pleiotropic impacts of macrophage and microglial deficiency on development in rats with targeted mutation of the Csf1r locus. J. Immunol. 2018, 201, 2683–2699.
  91. Fan, D.; Yue, Q.; Chen, J.; Wang, C.; Yu, R.; Jin, Z.; Yin, S.; Wang, Q.; Chen, L.; Liao, X.; et al. Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells. Oncoimmunology 2021, 10, 1932061.
  92. Ma, D.; Zhan, D.; Fu, Y.; Wei, S.; Lal, B.; Wang, J.; Li, Y.; Lopez-Bertoni, H.; Yalcin, F.; Dzaye, O. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1. Cancer Lett. 2021, 517, 35–45.
  93. Huynh, K.K.; Eskelinen, E.L.; Scott, C.C.; Malevanets, A.; Saftig, P.; Grinstein, S. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 2007, 26, 313–324.
  94. Meng, F.; Li, W.; Li, C.; Gao, Z.; Guo, K.; Song, S. CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma. Int. J. Oncol. 2015, 46, 1109–1120.
  95. Zhao, C.; Zheng, S.; Yan, Z.; Deng, Z.; Wang, R.; Zhang, B. CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2. Oncol. Rep. 2020, 43, 571–580.
  96. Huang, Y.; Motta, E.; Nanvuma, C.; Kuhrt, L.D.; Yuan, Y.; Xia, P.; Lubas, M.; Zhu, S.; Schnauss, M.; Qazi, N.; et al. Microglia/macrophage-derived human CCL18 promotes glioma progression via CCR8-ACP5 axis analyzed in humanized slice model. Cell Rep. 2022, 39, 110670.
  97. Richard, Q.; Laurenge, A.; Mallat, M.; Sanson, M.; Castro-Vega, L.J. New insights into the Immune TME of adult-type diffuse gliomas. Curr. Opin. Neurol. 2022, 35, 794–802.
  98. Metallo, C.M.; Gameiro, P.A.; Bell, E.L.; Mattaini, K.R.; Yang, J.; Hiller, K.; Jewell, C.M.; Johnson, Z.R.; Irvine, D.J.; Guarente, L. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481, 380–384.
  99. Wang, S.; Li, L.; Zuo, S.; Kong, L.; Wei, J.; Dong, J. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDHWT glioblastoma. Front. Immunol. 2022, 13, 5822.
  100. Vaidya, M.; Jentsch, J.A.; Peters, S.; Keul, P.; Weske, S.; Gräler, M.H.; Mladenov, E.; Iliakis, G.; Heusch, G.; Levkau, B. Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages. J. Lipid Res. 2019, 60, 506–515.
  101. Wise, D.R.; Ward, P.S.; Shay, J.E.; Cross, J.R.; Gruber, J.J.; Sachdeva, U.M.; Platt, J.M.; DeMatteo, R.G.; Simon, M.C.; Thompson, C.B. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. USA 2011, 108, 19611–19616.
  102. Tkach, M.; Théry, C. Communication by extracellular vesicles: Where we are and where we need to go. Cell 2016, 164, 1226–1232.
  103. Zhang, H.-G.; Grizzle, W.E. Exosomes and Cancer: A Newly Described Pathway of Immune Suppression Exosomes and Cancer. Clin. Cancer Res. 2011, 17, 959–964.
  104. Tadokoro, H.; Umezu, T.; Ohyashiki, K.; Hirano, T.; Ohyashiki, J.H. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 2013, 288, 34343–34351.
  105. King, H.W.; Michael, M.Z.; Gleadle, J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12, 1–10.
  106. Johnson, D.E.; O’Keefe, R.A.; Grandis, J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018, 15, 234–248.
  107. Zhang, G.; Zhong, L.; Luo, H.; Wang, S. MicroRNA-155-3p promotes breast cancer progression through down-regulating CADM1. OncoTargets Ther. 2019, 12, 7993.
  108. Wu, X.; Wang, Y.; Yu, T.; Nie, E.; Hu, Q.; Wu, W.; Zhi, T.; Jiang, K.; Wang, X.; Lu, X. Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro-Oncol. 2017, 19, 1195–1205.
  109. Xu, J.; Zhang, J.; Zhang, Z.; Gao, Z.; Qi, Y.; Qiu, W.; Pan, Z.; Guo, Q.; Li, B.; Zhao, S. Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction. Cell Death Dis. 2021, 12, 1–16.
  110. Qian, M.; Wang, S.; Guo, X.; Wang, J.; Zhang, Z.; Qiu, W.; Gao, X.; Chen, Z.; Xu, J.; Zhao, R. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways. Oncogene 2020, 39, 428–442.
  111. Zhang, J.; Sarkar, S.; Cua, R.; Zhou, Y.; Hader, W.; Yong, V.W. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 2012, 33, 312–319.
  112. Li, H.; Jiang, T.; Li, M.-Q.; Zheng, X.-L.; Zhao, G.-J. Transcriptional regulation of macrophages polarization by MicroRNAs. Front. Immunol. 2018, 9, 1175.
  113. Zhang, C.; Zhou, Y.; Gao, Y.; Zhu, Z.; Zeng, X.; Liang, W.; Sun, S.; Chen, X.; Wang, H. Radiated glioblastoma cell-derived exosomal circ_0012381 induce M2 polarization of microglia to promote the growth of glioblastoma by CCL2/CCR2 axis. J. Transl. Med. 2022, 20, 388.
  114. Hajji, N.; Garcia-Revilla, J.; Soto, M.S.; Perryman, R.; Symington, J.; Quarles, C.C.; Healey, D.R.; Guo, Y.; Orta-Vazquez, M.L.; Mateos-Cordero, S.; et al. Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. J. Clin. Investig. 2022, 132, e142137.
  115. Yang, J.; Sun, G.; Hu, Y.; Yang, J.; Shi, Y.; Liu, H.; Li, C.; Wang, Y.; Lv, Z.; Niu, J. Extracellular vesicle lncRNA metastasis-associated lung adenocarcinoma transcript 1 released from glioma stem cells modulates the inflammatory response of microglia after lipopolysaccharide stimulation through regulating miR-129-5p/high mobility group box-1 protein axis. Front. Immunol. 2020, 10, 3161.
  116. Arienti, C.; Pignatta, S.; Zanoni, M.; Zamagni, A.; Cortesi, M.; Sarnelli, A.; Romeo, A.; Arpa, D.; Longobardi, P.; Bartolini, D.; et al. High-pressure oxygen rewires glucose metabolism of patient-derived glioblastoma cells and fuels inflammasome response. Cancer Lett. 2021, 506, 152–166.
  117. Wang, L.; Yang, C.; Wang, Q.; Liu, Q.; Wang, Y.; Zhou, J.; Li, Y.; Tan, Y.; Kang, C. Homotrimer cavin1 interacts with caveolin1 to facilitate tumor growth and activate microglia through extracellular vesicles in glioma. Theranostics 2020, 10, 6674–6694.
  118. Serpe, C.; Monaco, L.; Relucenti, M.; Iovino, L.; Familiari, P.; Scavizzi, F.; Raspa, M.; Familiari, G.; Civiero, L.; D’Agnano, I.; et al. Microglia-Derived Small Extracellular Vesicles Reduce Glioma Growth by Modifying Tumor Cell Metabolism and Enhancing Glutamate Clearance through miR-124. Cells 2021, 10, 2066.
  119. Hong, S.; You, J.Y.; Paek, K.; Park, J.; Kang, S.J.; Han, E.H.; Choi, N.; Chung, S.; Rhee, W.J.; Kim, J.A. Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment. Theranostics 2021, 11, 9687–9704.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback